Affordable Access

deepdyve-link
Publisher Website

Hypercoagulability in Cushing Syndrome, Prevalence of Thrombotic Events: A Large, Single-Center, Retrospective Study

Authors
  • Suarez, Maria Gabriela1, 2
  • Stack, Madeleine2
  • Hinojosa-Amaya, Jose Miguel2, 3, 4
  • Mitchell, Michael D5
  • Varlamov, Elena V1, 2, 3
  • Yedinak, Chris G2, 3
  • Cetas, Justin S2, 3, 6
  • Sheppard, Brett7
  • Fleseriu, Maria1, 2, 3
  • 1 Department of Medicine (Endocrinology), Oregon Health & Science University, USA , (United States)
  • 2 Department of Neurological Surgery, Oregon Health & Science University, USA , (United States)
  • 3 Northwest Pituitary Center, Oregon Health & Science University, USA , (United States)
  • 4 Endocrinology Division, Department of Medicine, Hospital Universitario “Dr. Jose E. Gonzalez”, Universidad Autonoma de Nuevo Leon, Mexico , (Mexico)
  • 5 University of Iowa
  • 6 Operative Care Division, Portland Veterans Administration Hospital, USA , (United States)
  • 7 Department of General Surgery, Oregon Health & Science University, USA , (United States)
Type
Published Article
Journal
Journal of the Endocrine Society
Publisher
The Endocrine Society
Publication Date
Dec 15, 2019
Volume
4
Issue
2
Identifiers
DOI: 10.1210/jendso/bvz033
PMID: 32064411
PMCID: PMC7009121
Source
PubMed Central
Keywords
License
Unknown

Abstract

Background The risk of Cushing syndrome (CS) patients experiencing a thrombotic event (TE) is significantly higher (odds ratio; OR 18%) than that of the general population. However, there are currently no anticoagulation guidelines. Methods A retrospective, single-center, longitudinal study of patients undergoing all types of treatment—surgical (pituitary, unilateral, and bilateral adrenalectomy) and medical treatment—was undertaken. TEs were recorded at any point up until last patient follow-up; myocardial infarction (MI), deep venous thrombosis (DVT), and pulmonary embolism (PE) or stroke. Patients’ doses and complications of anticoagulation were recorded. Results Included were 208 patients; a total of 165 (79.3%) were women, and mean age at presentation was 44 ± 14.7 years. Thirty-nine (18.2%) patients had a TE; extremity DVT (38%), cerebrovascular accident (27%), MI (21%), and PE (14%). Of 56 TEs, 27 (48%) were arterial and 29 (52%) were venous. Patients who underwent bilateral adrenalectomy (BLA) had an odds ratio of 3.74 (95% CI 1.69-8.27) of developing a TE. Of patients with TEs, 40.5% experienced the event within the first 60 days after surgery. Baseline 24-hour urinary free cortisol levels did not differ in patients with or without TE after BLA. Of 197 patients who underwent surgery, 50 (25.38%) received anticoagulation after surgery, with 2% having bleeding complications. Conclusions The risk of TEs in patients with CS was approximately 20%. Many patients had more than 1 event, with higher risk 30 to 60 days postoperatively. The optimal prophylactic anticoagulation duration is unknown, but most likely needs to continue up to 60 days postoperatively, particularly after BLA.

Report this publication

Statistics

Seen <100 times